



**MEDI LIFESTYLE LIMITED
AND ITS SUBSIDIARIES**

Company Registration No: 201117734D

**CONDENSED INTERIM FINANCIAL STATEMENTS
FOR THE THIRD QUARTER (“3Q2022”) AND NINE MONTHS (“9M2022”)
ENDED 30 SEPTEMBER 2022**

In view of the disclaimer of opinion on going concern assumption issued by the Company’s independent auditors, Mazars LLP, on the audited financial statements of the Group for the financial ended 31 December 2021, the Company is required by the Singapore Exchange Securities Trading Limited (“Exchange”) to announce its quarterly financial statements pursuant to Catalist Rule 705.

Contents

	Page
A. Condensed interim consolidated statement of profit or loss and other comprehensive income	2
B. Condensed interim statements of financial position	3
C. Condensed interim statements of changes in equity	4
D. Condensed interim consolidated statement of cash flows	5
E. Notes to the condensed interim consolidated financial statements	6
F. Other information required by Catalist Rule Appendix 7C	17

A. CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

Group	Note	3 months ended 30 September ("3Q")			9 months ended 30 September ("9M")		
		3Q2022 RM'000 (Unaudited)	3Q2021 RM'000 (Unaudited)	Change + / (-) %	9M2022 RM'000 (Unaudited)	9M2021 RM'000 (Unaudited)	Change + / (-) %
Revenue	4	799	147	443.5	2,133	556	283.6
Cost of sales		(655)	(90)	627.8	(1,703)	(433)	293.3
Gross profit		144	57	152.6	430	123	249.6
Other operating income		1,075	-	n.m.	1,362	3	n.m.
Administrative expenses		(1,257)	(1,404)	(10.5)	(4,110)	(3,527)	16.5
Exchange (loss)/gain		(118)	7	n.m.	(223)	(52)	328.8
Other operating expenses		(130)	1	n.m.	(133)	(1,847)	(92.8)
Finance costs		(59)	(136)	(56.6)	(241)	(314)	(23.2)
Loss before tax	5	(345)	(1,475)	(76.6)	(2,915)	(5,614)	(48.1)
Income tax		-	-	-	-	-	-
Loss for the period from continuing operations		(345)	(1,475)	(76.6)	(2,915)	(5,614)	(48.1)
Discontinued Operations							
Loss for the period from discontinued operations	6	-	(2,570)	n.m.	-	(6,602)	n.m.
Loss for the period		(345)	(4,045)	(91.5)	(2,915)	(12,216)	(76.1)
Other comprehensive income/(loss), net of tax							
- Exchange differences on translation of foreign operations		141	105	34.3	(23)	131	n.m.
Total comprehensive loss for the period, net of tax		(204)	(3,940)	(94.8)	(2,938)	(12,085)	(75.7)
Total loss attributable to:							
Owners of the Company							
- Continuing operations		(345)	(1,475)	(76.6)	(2,915)	(5,614)	(48.1)
- Discontinued operations		-	(2,570)	n.m.	-	(6,602)	n.m.
Non-controlling interests							
- Continuing operations		-	-	-	-	-	-
		(345)	(4,045)	(91.5)	(2,915)	(12,216)	(76.1)
Total comprehensive loss attributable to:							
Owners of the Company		(204)	(3,940)	(94.8)	(2,938)	(12,085)	(75.7)
Non-controlling interests		-	-	-	-	-	-
		(204)	(3,940)	(94.8)	(2,938)	(12,085)	(75.7)
Loss per share for the period attributable to owners of the Company							
Basic (Malaysia sen)		(0.06)	(0.79)		(0.52)	(2.42)	
Diluted (Malaysia sen)		(0.06)	(0.79)		(0.52)	(2.42)	

n.m. denotes not meaningful

Note: The financial statements for 3Q2021 and 9M2021 have been presented after reclassifying HealthPro Pte Ltd under discontinued operations after placing it under provisional liquidation on 29 July 2021. The voluntary liquidation and appointment of a liquidator was approved at an extraordinary general meeting and a meeting of creditors on 27 August 2021. HealthPro Pte Ltd has been dissolved on 22 September 2022 following the completion of the voluntary liquidation.

B. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

	Note	Company		Group	
		As at 30 September 2022 RM'000 (Unaudited)	As at 31 December 2021 RM'000 (Audited)	As at 30 September 2022 RM'000 (Unaudited)	As at 31 December 2021 RM'000 (Audited)
Current assets					
Cash and bank balances		36	418	123	1,218
Trade receivables	7	-	-	1,022	494
Other receivables and prepayments	8	1,671	153	481	968
Inventories		-	-	47	47
		<u>1,707</u>	<u>571</u>	<u>1,673</u>	<u>2,727</u>
Non-current assets					
Property, plant and equipment	9	-	-	215	157
Right-of-use assets	10	-	-	454	946
Intangible assets	11	-	-	200	200
Subsidiaries		5,684	5,434	-	-
		<u>5,684</u>	<u>5,434</u>	<u>869</u>	<u>1,303</u>
Total assets		<u>7,391</u>	<u>6,005</u>	<u>2,542</u>	<u>4,030</u>
Current liabilities					
Trade payables		-	-	-	31
Other payables and other provisions	12	2,181	839	7,043	4,860
Borrowings	13	2,213	2,438	2,213	2,438
Lease liabilities	14	-	-	286	1,358
Contract liabilities		-	-	65	79
Income tax payable		-	-	34	34
		<u>4,394</u>	<u>3,277</u>	<u>9,641</u>	<u>8,800</u>
Non-current					
Lease liabilities	14	-	-	203	1,159
		<u>-</u>	<u>-</u>	<u>203</u>	<u>1,159</u>
Total liabilities		<u>4,394</u>	<u>3,277</u>	<u>9,844</u>	<u>9,959</u>
Capital and reserves					
Share capital		127,721	126,156	127,721	126,156
Treasury shares		(38)	(38)	(38)	(38)
Currency translation reserve		230	123	(1)	22
Capital reserve		3,893	3,893	3,893	3,893
Accumulated losses		(128,809)	(127,406)	(138,877)	(135,962)
Equity attributable to owners of the Company		2,997	2,728	(7,302)	(5,929)
Non-controlling interests		-	-	-	-
Net equity / (capital deficiency)		<u>2,997</u>	<u>2,728</u>	<u>(7,302)</u>	<u>(5,929)</u>
Total liabilities and equity		<u>7,391</u>	<u>6,005</u>	<u>2,542</u>	<u>4,030</u>

C. CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY

Company

	Share capital (RM'000)	Treasury shares (RM'000)	Accumulated losses (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Total (RM'000)
At 1 January 2022	126,156	(38)	(127,406)	3,893	123	2,728
Total comprehensive loss for the period	-	-	(1,403)	-	107	(1,296)
Transaction with owners:						
Increase in paid-up capital	1,600	-	-	-	-	1,600
Capitalised expenses	(35)	-	-	-	-	(35)
At 30 September 2022	127,721	(38)	(128,809)	3,893	230	2,997

Company

	Share capital (RM'000)	Treasury shares (RM'000)	Accumulated losses (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Total (RM'000)
At 1 January 2021	119,718	(38)	(106,065)	3,526	(69)	17,072
Total comprehensive loss for the period	-	-	(1,459)	-	172	(1,287)
Transaction with owners:						
Increase in paid-up capital	1,542	-	-	-	-	1,542
Capitalised expenses	(49)	-	-	-	-	(49)
At 30 September 2021	121,211	(38)	(107,524)	3,526	103	17,278

Group

	Share capital (RM'000)	Treasury shares (RM'000)	Retained earnings (Accumulated losses) (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Equity attributable to owners of the Company (RM'000)	Non-controlling interests (RM'000)	Total equity (RM'000)
At 1 January 2022	126,156	(38)	(135,962)	3,893	22	(5,929)	-	(5,929)
Loss for the year	-	-	(2,915)	-	-	(2,915)	-	(2,915)
Other comprehensive income								
- Currency translation difference arising from consolidation	-	-	-	-	(23)	(23)	-	(23)
Transaction with owners:								
Increase in paid-up capital	1,600	-	-	-	-	1,600	-	1,600
Capitalised expenses	(35)	-	-	-	-	(35)	-	(35)
At 30 September 2022	127,721	(38)	(138,877)	3,893	(1)	(7,302)	-	(7,302)

Group

	Share capital (RM'000)	Treasury shares (RM'000)	Retained earnings (Accumulated losses) (RM'000)	Capital reserve (RM'000)	Currency translation reserve (RM'000)	Equity attributable to owners of the Company (RM'000)	Non-controlling interests (RM'000)	Total equity (RM'000)
At 1 January 2021	119,718	(38)	(112,238)	3,526	(3,360)	7,608	-	7,608
Loss for the year	-	-	(12,216)	-	-	(12,216)	-	(12,216)
Other comprehensive income								
- Exchange difference on translating foreign operations	-	-	-	-	131	131	-	131
Transaction with owners:								
Increase in paid-up capital	1,542	-	-	-	-	1,542	-	1,542
Capitalised expenses	(49)	-	-	-	-	(49)	-	(49)
At 30 September 2021	121,211	(38)	(124,454)	3,526	(3,229)	(2,984)	-	(2,984)

D. INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

Group	3 Months ended		9 Months ended	
	30 September ("3Q")		30 September ("9M")	
	3Q2022	3Q2021	9M2022	9M2021
	RM'000	RM'000	RM'000	RM'000
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES				
Loss before tax:				
- Continuing operations	(345)	(1,475)	(2,915)	(5,614)
- Discontinued operations	-	(2,570)	-	(6,602)
	(345)	(4,045)	(2,915)	(12,216)
Adjustments for:				
Depreciation of property, plant and equipment	13	24	38	61
Depreciation of right-of-use assets	68	58	332	2,793
Loss on termination of lease	59	-	62	-
Gain on termination of lease	(1,019)	-	(1,019)	-
Impairment of goodwill	-	-	-	1,840
Impairment of receivables	71	-	71	-
Loss from liquidation of subsidiary	-	2,437	-	2,437
Interest expenses	59	137	241	488
Operating loss before working capital changes	(1,094)	(1,389)	(3,190)	(4,597)
Inventories	(7)	4	-	2
Trade and other receivables and prepayments	387	(71)	(72)	(302)
Contract liabilities	(15)	-	-	-
Trade and other payables and other provisions	(305)	785	2,117	1,198
Cash used in operating activities	(1,034)	(671)	(1,145)	(3,699)
Interest paid	(187)	-	(187)	-
Net cash used in operating activities	(1,221)	(671)	(1,332)	(3,699)
CASH FLOWS FROM INVESTING ACTIVITIES				
Purchase of property, plant and equipment	(11)	(44)	(96)	(111)
Net cash used in investing activities	(11)	(44)	(96)	(111)
CASH FLOWS FROM FINANCING ACTIVITIES				
Repayment of lease liability	(218)	(62)	(930)	(2,982)
Convertible Loans	-	(14)	-	5,081
Repayment of convertible loans	(323)	-	(323)	-
Proceeds from issuance of ordinary shares	1,600	-	1,600	1,542
Capitalised transaction costs on issuance of ordinary shares	(28)	-	(35)	(49)
Net cash generated from / (used in) financing activities	1,031	(76)	312	3,592
Net decrease in cash and cash equivalents	(201)	(791)	(1,116)	(218)
Cash and cash equivalents at beginning of the period	317	1,074	1,218	496
Currency translation difference of cash and cash equivalents at beginning of the period	7	(2)	21	3
Cash and cash equivalents at end of period	123	281	123	281
<i>Cash and bank balances comprise:</i>				
Cash and bank balances	123	281	123	281
Cash and cash equivalents at end of period	123	281	123	281

E. SELECTED NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate and group information

Medi Lifestyle Limited (formerly known as IEV Holdings Limited) (the “Company”) (Registration No. 201117734D) is incorporated in Singapore with its principal place of business at 380 Jalan Besar, #09-05 ARC 380, Singapore 209000 and registered office at 80 Robinson Road #02-00, Singapore 068898. Its shares are publicly traded on the Catalist board of the Singapore Exchange.

The principal activity of the Company is that of investment holding. The principal activities of its subsidiaries are in the Healthcare and Wellness sector. The financial results presented under continuing operations for the three months (“3Q2022”) and nine months (“9M2022”) ended 30 September 2022 comprise of (i) the Healthcare and Wellness sector which includes 1 postpartum care centres as well as 2 chiropractic and physiotherapy centre in Malaysia; and (ii) Outsourced services in Malaysia and Singapore including human resource recruitment and payroll, and IT support services.

During the financial year ended 31 December 2021, the voluntary liquidation of HealthPro Pte Ltd and appointment of a liquidator was approved at an extraordinary general meeting and a meeting of creditors on 27 August 2021, whereupon the subsidiary was reclassified under discontinued operations and its assets and liabilities being held under liquidation were de-consolidated from the Group’s condensed interim financial statements. HealthPro Pte Ltd was dissolved on 22 September 2022. In addition, HealthPro Group (S) Pte Ltd and HealthPro Group (M) Sdn Bhd had entered into Share Sale Agreements to fully acquire Impact BPO Services Pte Ltd and Impact BPO Sdn Bhd respectively, with effect from 1 October 2021. Both these newly acquired and wholly-owned subsidiaries are principally engaged in outsourced support and recruitment services in Singapore and Malaysia. The Group had also on 31 December 2021, received approval from the Accounting and Corporate Regulatory Authority of Singapore and completed the strike off of its wholly-owned subsidiary, IEV Energy Investment Pte. Ltd.

2. Basis of preparation

The condensed interim financial statements for 3Q2022 and 9M2022 have been prepared in accordance with SFRS(I) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last audited financial statements for the twelve months ended 31 December 2021.

The interim statements of financial position of the Company and its subsidiaries as at 30 September 2022 and related interim consolidated profit or loss and other comprehensive income, interim consolidated statement of changes in equity and interim consolidated statement of cash flows for 3Q2022 and 9M2022 and certain explanatory notes have not been independently audited or reviewed.

Except as disclosed in Note 2.1 below, the Group has applied the same accounting policies and methods of computation in the financial statements for current financial period reported on, as those applied in the Group’s most recently audited financial statements for the financial year ended 31 December 2021, which were prepared in accordance with Singapore Financial Reporting Standards (International).

The individual financial statements of each Group entity are measured and presented in the currency of the primary economic environment in which the entity operates its functional currency. The functional currency of the Company is Singapore Dollar (“S\$”) while the consolidated financial statements of the Group and the statement of financial position and changes in equity of the Company are presented in Malaysia Ringgit (“RM”).

2.1 New and amended standards adopted by the Group

The Group has adopted all the new and revised Singapore Financial Reporting Standards (International) (“SFRS(I)”) and SFRS(I) Interpretations (“SFRS(I) INTs”) that are relevant to its operations and effective for annual periods beginning on or after 1 January 2022, where applicable. The adoption of these standards from the effective date has not resulted in material adjustments to the financial position, results of operations or cash flows of the Group for 3Q2022 and 9M2022. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2 Use of estimates and judgement

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions about the carrying amount of assets and liabilities that were not readily apparent from other sources in the application of the Group's accounting policies. Estimates and judgements are continually evaluated and are based on historical experience and other factors considered to be reasonable under the circumstances. Actual results may differ from these estimates.

Other than the following disclosure, there are no critical judgement made by management in the process of applying the Group's accounting policies which may have the most significant effect on the amounts recognised in the financial statements.

Impairment of investment in subsidiaries

Management exercises their judgement in estimating recoverable amounts of its investment in subsidiaries of the Company. The recoverable amounts of the investments are reviewed at the end of each reporting period to determine whether there is any indication that those investments have suffered an impairment loss. If any such indication exists, the recoverable amount is estimated in order to determine the extent of the impairment loss (if any). Recoverable amount is the higher of fair value less costs of disposal and value-in-use. In assessing value-in-use, management needs to estimate the future cash flows expected from the cash-generating units and an appropriate discount rate in order to calculate the present value of the future cash flows.

Calculation of loss allowance for trade and other receivables

When measuring expected credit loss ("ECL") the Group uses reasonable and supportable forward-looking information, which is based on assumptions for the future movement of different economic drivers and how these drivers will affect each other. Loss given default is an estimate of the loss arising on default. It is based on the difference between the contractual cash flows due and those that the lender would expect to receive, taking into account cash flows from collateral and integral credit enhancements. Probability of default constitutes a key input in measuring ECL. Probability of default is an estimate of the likelihood of default over a given time horizon, the calculation of which includes historical data, assumptions and expectations of future conditions.

2.3 Going concern assumption

As at 30 September 2022, the Group's current liabilities exceeded its current assets by RM8.0 million. In addition, the Group incurred a net loss of RM2.9 million and net operating cash outflow of RM1.3 million for the nine months ended 30 September 2022. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. To support the financial statements having been prepared on a going concern basis and to ensure the adequacy of funds required to meet its obligations, working capital and capital commitment needs, the Group prepared a 12-month consolidated cash flow forecast from 1 November 2022 ("**Cash Flow Forecast**"). In preparing the Cash Flow Forecast, the management has taken the followings into consideration:

- (i) Entry into non-redeemable convertible loan notes in October 2022 raising S\$647,000 in October 2022 and expected capital to be raised of up to S\$1.7 million which may be in equity, debt or combination thereof, to finance capital outlays set out in (ii) below, to repay convertible loans with principal sum of S\$0.15 million and accumulated interest, and to service interest payments on non-redeemable convertible loan notes issued in October 2022 with aggregate principal sum of S\$0.65 million;
- (ii) The Group plans to spend on capital outlays of up to S\$0.5 million, subject to sufficient funds being raised, which are required for four new chiropractic and physiotherapy, and such a sum is not yet contractually committed. The chiropractic and physiotherapy centres are to commence operations over the course of 2023;
- (iii) Letters of undertaking have been obtained from creditors, to not demand repayment of the amounts owing to them of approximately RM1.6 million until resources permit; and
- (iv) The roll-over of outstanding convertible loans of S\$0.2 million into three (3) year term loans, maturing in October 2025.

2.4 Board's comments on going concern assumption

In the assessment of Group's going concern, the Board has considered the followings:

- (a) the Cash Flow Forecast prepared by management, including estimated earnings from the Healthcare Sector and the Outsourced Services Sector, as mentioned above;
- (b) planned fund-raising of up to S\$1.7 million which may be in equity, debt or combination thereof, to finance capital outlays elaborated in Para 2.3(iii) above, to repay convertible loans with principal sum of S\$0.15 million and

accumulated interest, and to service interest on non-redeemable convertible loan notes with aggregate principal sum of S\$0.65 million;

- (c) as part of the planned fund-raising in (b), the successful fund-raising in October 2022 of non-redeemable convertible loan notes with aggregate principal sum of S\$0.65 million with a tenure of two years which may be converted into new ordinary Shares at the option of the Company;
- (d) the rollover of outstanding convertible loans of S\$0.2 million into 3-year term loans maturing in October 2025;
- (e) letter of undertaking from creditors to not demand for amounts owing to them of approximately RM1.6 million until the resources permit; and
- (f) letter of financial support from a substantial shareholder who has agreed to provide up to S\$5.0 million for the Group to meet its liabilities and its normal operating expenses as and when required.

Barring any unforeseen circumstances, the Board is of the opinion that the Group should be able to meet its working capital commitments for the next 12 months and the Group's financial statements be prepared on a going concern basis.

3. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segmental and revenue information

The Group's reportable segments were identified as follows:

Continuing Operations consist of:

- Corporate – investment holding activities
- Healthcare – postpartum care and chiropractic & physiotherapy services.
- Outsourced Services – human resource recruitment and payroll, information technology and other outsourced support services

Discontinued Operations consist of:

- Exploration & Production – IEV Energy Investment Pte Ltd under voluntary liquidation and struck off on 28 December 2021
- Healthcare – HealthPro Pte Ltd placed under creditors' liquidation and dissolved on 22 September 2022

These operating segments are reported in a manner consistent with internal reporting provided to the Chief Executive Officer who is responsible for allocating resources and assessing performance of the operating segments.

4.1 Reportable Segments

The segment analysis on the Group's results for three months ended 30 September 2022 ("3Q2022") and 30 September 2021 ("3Q2021") are as follows:-

	Continuing Operations						Discontinued Operations				Combined	
	Healthcare		Corporate		Outsourced Services		Exploration & Production		Healthcare		3Q2022 RM'000	3Q2021 RM'000
	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000		
REVENUE												
Total Sales	207	147	-	-	610	-	-	-	-	-	817	147
Inter-segment sales	-	-	-	-	(18)	-	-	-	-	-	(18)	-
External sales	207	147	-	-	592	-	-	-	-	-	799	147
RESULTS												
Segment results	378	(1,337)	(503)	(2)	(161)	-	-	-	-	(2,569)	(286)	(3,908)
Finance costs	(8)	(7)	(51)	(129)	-	-	-	-	-	(1)	(59)	(137)
	370	(1,344)	(554)	(131)	(161)	-	-	-	-	(2,570)	(345)	(4,045)
Taxation											-	-
Loss for the Year											(345)	(4,045)
Loss attributable to												
- owners of the parent											(345)	(4,045)
- non-controlling interest											-	-
Profit/(Loss) for the Year											(345)	(4,045)
Depreciation of property, plant and equipment	(8)	(24)	(5)	-	-	-	-	-	-	-	(13)	(24)
Depreciation of right-of-use asset	-	-	(68)	(50)	-	-	-	-	-	(8)	(68)	(58)

	Continuing Operations						Discontinued Operations				Combined	
	Healthcare		Corporate		Outsourced Services		Exploration & Production		Healthcare			
	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000	3Q2022 RM'000	3Q2021 RM'000
Impairment of trade receivables	-	-	-	-	(71)	-	-	-	-	-	(71)	-
Loss on termination of lease	(59)	-	-	-	-	-	-	-	-	-	(59)	-
Gain on termination of lease	1,019	-	-	-	-	-	-	-	-	-	1,019	-
Loss from liquidation of subsidiary	-	-	-	-	-	-	-	-	(2,437)	-	-	(2,437)

The segment analysis on the Group's results for nine months ended 30 September 2022 ("9M2022") and 30 September 2021 ("9M2021") are as follows:-

	Continuing Operations						Discontinued Operations				Combined	
	Healthcare		Corporate		Outsourced Services		Exploration & Production		Healthcare			
	9M2022 RM'000	9M2021 RM'000	9M 2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000
REVENUE												
Total sales	464	556	-	-	1,719	-	-	-	-	-	2,183	556
Inter-segment sales	-	-	-	-	(50)	-	-	-	-	-	(50)	-
External sales	464	556	-	-	1,669	-	-	-	-	-	2,133	556
RESULTS												
Segment results	(957)	(4,035)	(1,433)	(1,265)	(284)	-	-	(14)	-	(6,414)	(2,674)	(11,728)
Finance costs	(42)	(10)	(193)	(304)	(6)	-	-	-	-	(174)	(241)	(488)
Taxation	(999)	(4,045)	(1,626)	(1,569)	(290)	-	-	(14)	-	(6,588)	(2,915)	(12,216)
Loss for the Year											(2,915)	(12,216)
Loss attributable to - owners of the parent											(2,915)	(12,216)
- non-controlling interest											-	-
Profit/(Loss) for the Year											(2,915)	(12,216)
Depreciation of property, plant and equipment	(25)	(59)	(12)	-	(1)	-	-	-	-	(2)	(38)	(61)
Depreciation of right-of-use asset	-	-	(201)	(66)	(131)	-	-	-	-	(2,727)	(332)	(2,793)
Impairment of goodwill	-	(1,840)	-	-	-	-	-	-	-	-	-	(1,840)
Loss on termination of lease	59	-	-	-	(3)	-	-	-	-	-	(62)	-

	Continuing Operations						Discontinued Operations				Combined	
	Healthcare		Corporate		Outsourced Services		Exploration & Production		Healthcare			
	9M2022 RM'000	9M2021 RM'000	9M 2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000	9M2022 RM'000	9M2021 RM'000
Gain on termination of lease	1,019	-	-	-	-	-	-	-	-	-	1,019	-
Impairment of trade receivables	-	-	-	-	(71)	-	-	-	-	-	(71)	-
Loss from liquidation of subsidiary	-	-	-	-	-	-	-	-	(2,437)	-	-	(2,437)

	Continuing Operations						Discontinued Operations				Combined	
	Healthcare		Corporate		Outsourced Services		Exploration & Production		Healthcare			
	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000	As at 30 September 2022 RM'000	As at 31 December 2021 RM'000
Assets												
Segment assets	1,192	1,913	44	426	1,306	1,691	-	-	-	-	2,542	4,030
Sub-Total	1,192	1,913	44	426	1,306	1,691	-	-	-	-	2,542	4,030
Unallocated assets											-	-
Consolidated total assets											2,542	4,030
Liabilities												
Segment liabilities	3,966	5,030	4,393	3,245	1,450	1,647	-	-	-	-	9,809	9,922
Sub-Total	3,966	5,030	4,393	3,245	1,450	1,647	-	-	-	-	9,809	9,922
Unallocated liabilities											35	37
Consolidated total liabilities											9,844	9,959

4.2 Disaggregation of revenue

<u>Group</u>	3 months ended			9 months ended		
	30 September ("3Q")			30 September ("9M")		
	3Q2022	3Q2021	Change	9M2022	9M2021	Change
	RM'000	RM'000	+/(-)%	RM'000	RM'000	+/(-)%
Continuing operations						
(Healthcare Sector)						
Rendering of confinement centre services – Over time	157	122	28.7	347	473	(26.7)
Rendering of permanent placement services – Over time	247	-	n.m.	943	-	n.m.
Rendering of human resource and payroll services – Over time	345	-	n.m.	726	-	n.m.
Rendering of chiro & physio services – Point in time	38	8	387.5	73	10	630.0
Sale of related products – Point in time	12	17	(29.4)	44	73	(39.7)
	799	147	443.5	2,133	556	283.6

4.3 Geographical Segment

The following table shows the distribution of the Group's combined sales based on geographical location of customers.

<u>Group</u>	3 months ended		9 months ended	
	30 September ("3Q")		30 September ("9M")	
	3Q2022	3Q2021	9M2022	9M2021
	RM'000	RM'000	RM'000	RM'000
<u>Continuing operations</u>				
Malaysia	410	147	814	556
Singapore	389	-	1,319	-
Revenue from continuing operations	799	147	2,133	556
<u>Discontinued operations</u>				
Revenue from discontinued operations	-	-	-	-
Total revenue	799	147	2,133	556

5. Loss before tax

Loss for the financial period from continuing operations is arrived after charging the following:

<u>Group</u>	3 months ended			9 months ended		
	30 September ("3Q")			30 September ("9M")		
	3Q2022	3Q2021	Change	9M2022	9M2021	Change
	RM'000	RM'000	+/(-)%	RM'000	RM'000	+/(-)%
Interest expense	(59)	(136)	(56.6)	(241)	(314)	(23.2)
Depreciation of property, plant and equipment	(13)	(24)	(45.8)	(38)	(59)	(35.6)
Depreciation of right-of-use asset	(68)	(50)	36.0	(332)	(66)	403.0
Loss on termination of lease	(59)	-	n.m.	(62)	-	n.m.
Gain on termination of lease	1,019	-	n.m.	1,019	-	n.m.
Impairment of trade receivables	(71)	-	n.m.	(71)	-	n.m.
Impairment of goodwill	-	-	-	-	(1,840)	n.m.

6. Discontinued operations

Financial statements for 3Q2021 and 9M2021 have been presented after:

- (i) reclassifying HealthPro Pte Ltd under discontinued operations after placing it under provisional liquidation on 29 July 2021. The voluntary liquidation of HealthPro Pte Ltd and appointment of a liquidator was approved at an extraordinary general meeting and a meeting of creditors on 27 August 2021;
- (ii) the exit from the exploration and production sector as announced on 10 January 2018 and 13 September 2019 in relation to the member's voluntary liquidation of PT IEV Pabuaran KSO, which was completed on 11 January 2021; and
- (iii) striking off of IEV Energy Investment Pte Ltd which was completed on 28 December 2021.

Results of the discontinued operations are as follow:

<u>Group</u>	3 months ended			9 months ended		
	30 September ("3Q")			30 September ("9M")		
	3Q2022	3Q2021	Change	9M2022	9M2021	Change
	RM'000	RM'000	+/(-)%	RM'000	RM'000	+/(-)%
Discontinued operations						
Revenue	-	-	-	-	-	-
Cost of sales	-	-	-	-	-	-
Gross profit	-	-	-	-	-	-
Other operating income	-	1	n.m.	-	129	n.m.
Administrative expenses	-	(133)	n.m.	-	(4,120)	n.m.
Exchange gain	-	-	n.m.	-	-	n.m.
Other operating expenses	-	(2,437)	n.m.	-	(2,437)	n.m.
Finance cost	-	(1)	n.m.	-	(174)	n.m.
Loss before tax	-	(2,570)	n.m.	-	(6,602)	n.m.
Income tax	-	-	-	-	-	-
Loss for the period from discontinued operations	-	(2,570)	n.m.	-	(6,602)	n.m.

Loss for the financial period from discontinued operations is arrived after charging the following:

<u>Group</u>	3 months ended			9 months ended		
	30 September ("3Q")			30 September ("9M")		
	3Q2022	3Q2021	Change	9M2022	9M2021	Change
	RM'000	RM'000	+/(-)%	RM'000	RM'000	+/(-)%
Interest expense	-	(1)	n.m.	-	(174)	n.m.
Depreciation of property, plant and equipment	-	-	n.m.	-	(2)	n.m.
Depreciation of right-of-use asset	-	(8)	n.m.	-	(2,727)	n.m.
Loss from liquidation of subsidiary	-	(2,437)	n.m.	-	(2,437)	n.m.

7. Trade receivables

	Company		Group	
	As at	As at	As at	As at
	30 September	31 December	30 September	31 December
	2022	2021	2022	2021
	RM'000	RM'000	RM'000	RM'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Third parties	-	-	1,245	643
Provision for doubtful debts – trade	-	-	(220)	(149)
Currency translation difference	-	-	(3)	-
	-	-	1,022	494

The trade receivables are derived from the outsourced services segment. Management applied the "simplified approach" for assessing expected credit losses for trade receivables from third parties. Under the simplified approach, the Group's management developed a provision matrix using historical credit loss rates adjusted with forward looking information to reflect the effects of the current and future economic conditions, economic factors impacted by COVID-19 pandemic. The main factors considered in determining the lifetime expected credit losses for these customers are debts past due more than 6 months and there was currently uncertainty over the recoverability of the debts. There is no provision for doubtful debts for the financial period in review.

8. Other receivables and prepayments

	Company		Group	
	As at 30 September 2022 RM'000 (Unaudited)	As at 31 December 2021 RM'000 (Audited)	As at 30 September 2022 RM'000 (Unaudited)	As at 31 December 2021 RM'000 (Audited)
Deposits	7	-	145	620
Prepayments	31	22	91	78
Accrued revenue	-	-	43	72
Cost recoverable from clients	-	-	202	196
Amount owing by subsidiaries	1,633	131	-	-
Others	-	-	-	2
	<u>1,671</u>	<u>153</u>	<u>481</u>	<u>968</u>

9. Property, plant and equipment

During the nine months ended 30 September 2022, the Group acquired property, plant and equipment amounting to RM96,000 (30 September 2021: RM111,000) comprising mainly office renovations and operational equipment.

10. Right-of-use assets

<u>Group</u>	Office unit RM'000	Confinement centre RM'000	Integrated units RM'000	Total RM'000
Cost:				
At 1 January 2021	-	13,216	-	13,216
Additions	385	1,752	794	2,931
Disposal of subsidiaries	-	(13,165)	-	(13,165)
Currency translation difference	2	(51)	1	(48)
At 31 December 2021	<u>387</u>	<u>1,752</u>	<u>795</u>	<u>2,934</u>
Additions	-	-	-	-
Currency translation difference	18	-	27	45
At 30 September 2022	<u>405</u>	<u>1,752</u>	<u>822</u>	<u>2,979</u>
Accumulated depreciation:				
At 1 January 2021	-	5,819	-	5,819
Depreciation for the year	77	3,258	159	3,494
Disposal of subsidiaries	-	(8,541)	-	(8,541)
Currency translation difference	-	(5)	-	(5)
At 31 December 2021	<u>77</u>	<u>531</u>	<u>159</u>	<u>767</u>
Depreciation for the period	132	-	200	332
Currency translation difference	11	-	9	20
At 30 September 2022	<u>220</u>	<u>531</u>	<u>368</u>	<u>1,119</u>
Termination of a lease:				
At 1 January 2021	-	-	-	-
Termination of a lease	185	1,221	-	1,406
At 30 September 2022	<u>185</u>	<u>1,221</u>	<u>-</u>	<u>1,406</u>
Carrying amount:				
At 30 September 2022	<u>-</u>	<u>-</u>	<u>454</u>	<u>454</u>
At 31 December 2021	<u>310</u>	<u>-</u>	<u>636</u>	<u>946</u>

11. Intangible Assets

During the 12 months ended 31 December 2021, the Group has launched a genetic screening service for Malaysia and Singapore markets under the brand name, Qodify where the intangible asset represents the purchase of brand name and internet platform from Malaysia Genomics Resources Berhad, a listed company in Malaysia. The aforementioned intangible assets are not ready for use. Hence, no amortisation of intangible assets was recorded for the current financial period.

12. Other payables and other provisions

	Company		Group	
	As at 30 September 2022 RM'000 (Unaudited)	As at 31 December 2021 RM'000 (Audited)	As at 30 September 2022 RM'000 (Unaudited)	As at 31 December 2021 RM'000 (Audited)
Amount owing to directors	339	-	2,327	1,279
Service tax payable	-	-	2	3
Accruals	1,357	546	2,381	1,129
Other payables	485	293	2,324	2,426
Others	-	-	9	23
	<u>2,181</u>	<u>839</u>	<u>7,043</u>	<u>4,860</u>

The amount owing to Directors of the Company relate to reimbursable disbursements incurred for business use and are repayable on demand.

13. Borrowings

In relation to the aggregate amount of the Group's borrowings and debt securities, the following are convertible loans outstanding at the end of the financial period reported on with comparative figures as at the end of the immediately preceding financial year.

Group and Company	Convertible Loan (RM'000)
At 1 January 2021	-
Proceeds from issue of convertible loans	6,954
Convertible loan amount classified as equity	(367)
Accumulated interest	794
Currency translation difference	2
Conversion of convertible loan to ordinary shares	(4,945)
At 31 December 2021	<u>2,438</u>
Accumulated interest	170
Repayment of convertible loans	(510)
Currency translation difference	115
At 30 September 2022	<u>2,213</u>
Amount repayable in one year or less, or on demand	<u>2,213</u>
Amount repayable after one year	<u>-</u>

Note: Convertible loans include accrued interests and recorded at fair value of the liability component. The fair value of the liability component is calculated using a market interest rate for an equivalent non-convertible loan at the date of issue. The residual amount, representing the value of the equity conversion component, is included in shareholders' equity in other reserves

Details of Convertible Loans

On 29 January 2021, the Company had entered into 1-year unsecured convertible loan agreements with 5 lenders, for an aggregate principal amount of S\$2.25 million. The maturity date is 12 months from the date of disbursement of the loan. The convertible loan bears an interest rate of 10.0% per annum. At the option of the lenders, these loans are convertible into 56,532,663 ordinary shares in the Company at the conversion price of S\$0.0398 per ordinary share on 3 specified dates (i.e. 30 June 2021, 30 September 2021 and/or 31 December 2021). Please refer to the Company's announcement dated 29 January 2021, 4 February 2021, 1 April 2021 and 12 April 2021 for more information.

As at 31 December 2021, S\$2.25 million of the convertible loans has been received by the Group and the Company received a Conversion Notice from I Concept Global Growth Fund (“**I Concept**”) to convert a loan principal sum of S\$1.6 million (“**Conversion Amount**”) into new ordinary shares in the Company. Accordingly, the Company has on 31 December 2021 allotted and issued 40,201,005 new ordinary shares of the Company at S\$0.0398 per ordinary share in favour of I Concept. Please refer to the Company’s announcement dated 31 December 2021 for more information.

On 7 November 2022, the Company entered into supplemental agreements with each Wong Soh Shyan and Wong Chui Chui to extend the maturity date of the unsecured convertible loan agreements for amounts totalling S\$200,000 till 31 October 2025. More details can be found in the Company’s announcement dated 8 November 2022.

14. Lease liabilities

The Group as lessee:

Group	As at 30 September 2022 RM’000	As at 31 December 2021 RM’000
Lease Liabilities		
Maturity analysis:		
Year 1	304	1,444
Year 2	207	1,191
Year 3	-	-
	511	2,635
Less: Unearned interest	(22)	(118)
	489	2,517
Analysed as:		
Current	286	1,358
Non-current	203	1,159
	489	2,517

15. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2022 and 31 December 2021:

	Company		Group	
	As at 30 September 2022 RM’000 (Unaudited)	As at 31 December 2021 RM’000 (Audited)	As at 30 September 2022 RM’000 (Unaudited)	As at 31 December 2021 RM’000 (Audited)
Financial Assets				
Financial assets at amortised cost	1,676	549	1,535	2,603
Financial Liabilities				
Financial liabilities at amortised cost	2,181	839	7,105	4,946
Borrowings	2,213	2,438	2,213	2,438
Lease liabilities	-	-	489	2,517

Financial assets consist of cash and bank balances, trade and other receivables, excluding prepayments, prepaid leases, tax recoverable and value-added tax receivables. Financial liabilities consist of convertible loans, trade and other payables and advances from a related party excluding value-added tax payables, withholding tax and income tax payable.

16. Subsequent events

In October 2022, the Company entered into non-redeemable convertible loan note agreements (“**CLNAs**”) with lenders for an aggregated principal amount of S\$647,000. These CLNAs have a tenure of two (2) years and the Company has the option to convert the principal amount into new ordinary shares of the Company prior to the maturity date. Please refer to the Company’s announcements dated 14, 18 and 31 October 2022 for more information.

F. OTHER INFORMATION REQUIRED BY CATALIST RULE APPENDIX 7C

1. Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation, share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

	Number of shares	Resultant issued and paid-up share capital (S\$)
Issued and paid-up share capital of the Company as at 31 December 2021 (excluding treasury shares)	552,768,971	49,391,018
Issuance of new ordinary shares on 19 July 2022	44,247,788	500,000
Issued and paid-up share capital of the Company as at 30 September 2022 (excluding treasury shares)	597,016,759	49,891,018

On 29 January 2021, the Company had entered into 1-year unsecured convertible loan agreements with 5 lenders, for an aggregate principal amount of S\$2.25 million. The maturity date is 12 months from the date of disbursement of the loan. The convertible loan bears an interest rate of 10.0% per annum. At the option of the lenders, these loans are convertible into 56,532,663 ordinary shares in the Company ("**Conversion Shares**") at the conversion price of S\$0.0398 per ordinary share on 3 specified dates (i.e. 30 June 2021, 30 September 2021 and/or 31 December 2021). Please refer to the Company's announcement dated 29 January 2021, 4 February 2021, 1 April 2021 and 12 April 2021 for more information. As at 31 December 2021, the Company received a Conversion Notice from I Concept Global Growth Fund ("**I Concept**") to convert a loan principal sum of S\$1.6 million into new ordinary shares in the Company. Accordingly, the Company has on 31 December 2021 allotted and issued 40,201,005 new ordinary shares of the Company at S\$0.0398 per ordinary share in favour of I Concept. Please refer to the Company's announcement dated 31 December 2021 for more information.

On 19 July 2022, the Company allotted and issued an aggregate of 44,247,788 ordinary shares at an issue price of S\$0.0113 per ordinary share pursuant to a share subscription exercise. Please refer to the Company's announcement dated 1 July 2022, 12 July 2022 and 20 July 2022 for more information.

Save as discussed above, there were no outstanding convertibles, share options or subsidiary holdings as at 30 September 2022. There were no outstanding convertibles, share options or subsidiary holdings as at 30 September 2021.

The total number of treasury shares as at 30 September 2022 and 31 December 2021 are presented below:

	As at 30 September 2022	As at 31 December 2021
Total number of treasury shares	200,000	200,000
Total number of ordinary shares	597,016,759	552,768,971
% of treasury shares over total number of ordinary shares	0.03%	0.04%

2. To show the total number of issued shares excluding treasury shares at the end of the current financial period and as at the end of the immediately preceding financial year

	As at 30 September 2022	As at 31 December 2021
Number of issued shares of the Company	597,216,759	552,968,971
Share buy-backs held as treasury shares	(200,000)	(200,000)
Number of issued shares excluding treasury shares	597,016,759	552,768,971

3. A statement showing all sales, transfers, disposal, cancellation and / or use of treasury shares as at the end of the current financial period reported on.

There were no sales, transfers, disposal, cancellation and /or use of treasury shares as at 30 September 2022.

4. A statement showing all sales, transfers, cancellation and / or use of subsidiary holdings as at the end of the current financial period reported on.

There were no sales, transfers, cancellation and / or use of subsidiary holdings as at 30 September 2022.

**5. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion:
a) Updates on the efforts taken to resolve each outstanding audit issue.
b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

This is not required for any audit issue that is a material uncertainty relating to going concern.

Please refer to Section E paragraph 2.4 for the Board's comments on going concern.

Further the Board is of the opinion that sufficient information has been disclosed for the trading of the Company's securities to continue in an orderly manner and the Board is not aware of any material information that requires disclosure but remains undisclosed as of the date of this announcement.

6. Earnings/(Loss) per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends

Group	3Q2022 (Malaysia sen)	3Q2021 (Malaysia sen)	9M2022 (Malaysia sen)	9M2021 (Malaysia sen)
Loss per ordinary share for the period based on the net loss attributable to shareholders of the Company:				
(i) Basic				
- from continuing operations	(0.06)	(0.29)	(0.52)	(1.11)
- from discontinued operations	-	(0.50)	-	(1.31)
	(0.06)	(0.79)	(0.52)	(2.42)
(ii) On a fully diluted basis	(0.06)	(0.79)	(0.52)	(2.42)
Weighted average number of ordinary shares	587,878,629	512,567,966	564,600,797	505,213,116

Basic and diluted loss per ordinary share have been computed based on the Group's loss attributable to owners of the parent and the weighted average number of ordinary shares in issue during the respective periods.

The basic and fully diluted loss per ordinary share for 3Q2022 and 3Q2021, 9M2022 and 9M2021 were the same as there were no potentially dilutive ordinary shares existing during 3Q2022 and 3Q2021, 9M2022 and 9M2021 respectively.

7. Net asset value (for the issuer and group) per ordinary share based on issued share capital of the issuer at the end of the (a) current period reported on and (b) immediately preceding financial year

	Net asset value per ordinary share (Malaysian sen)	
	As at 30 September 2022	As at 31 December 2021
Group	(1.2)	(1.1)
Company	0.5	0.5

Net asset value per ordinary share as at 30 September 2022 and 31 December 2021 have been calculated based on the aggregate number of ordinary shares of 597,016,759 and 552,768,971 as at the respective dates, excluding treasury shares.

8. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss any significant factors that affected the turnover, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors. It must also discuss any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on

Review of Statement of Comprehensive Income

Breakdown by business segments

Three Months ended 30 September 2022 and 30 September 2021

Business segment	3Q2022			3Q2021		
	Revenue (RM'000)	Gross Profit (RM'000)	GP Margin %	Revenue (RM'000)	Gross Profit (RM'000)	GP Margin %
Continuing Operations						
Healthcare services	207	64	30.9	147	57	38.8
Outsourced services	592	80	13.5	-	-	-
Total	799	144	18.0	147	57	38.8

Nine Months ended 30 September 2022 and 30 September 2021

Business segment	9M2022			9M2021		
	Revenue (RM'000)	Gross Profit (RM'000)	GP Margin %	Revenue (RM'000)	Gross Profit (RM'000)	GP Margin %
Continuing Operations						
Healthcare services	464	67	14.4	556	123	22.1
Outsourced services	1,669	363	21.8	-	-	-
Total	2,133	430	20.2	556	123	22.1

Continuing Operations

Revenue

Revenue for the Group in 3Q2022 increased by 443.5% to RM0.8 million from RM0.1 million in 3Q2021 due mainly to the acquisition of back-office support service companies ("**Outsourced Services**"), Impact BPO Services Pte Ltd ("**Impact SG**") in Singapore and Impact BPO Sdn Bhd ("**Impact MY**") in Malaysia on 1 October 2021. Outsourced Services include human resource recruitment and payroll and information technology services. Healthcare services from the postpartum centre in Petaling Jaya Malaysia ("**PJ Confinement Centre**") reported a 40.8% increase in 3Q2022 revenue of RM207 thousand from RM147 thousand in 3Q2021 due mainly to increased sales efforts to garner bookings during the quarter in review. For the same reasons, the Group's revenue for 9M2022 increased by 283.6% to RM2.1 million from RM0.6 million in 9M2021.

Gross Profit

The Group's gross profit for 3Q2022 increased by 152.6 % to RM144 thousand from the gross profit of RM57 thousand for 3Q2021 due mainly to the Outsourced Services segment, which generated gross profit of RM80 thousand during 3Q2022. Healthcare services reported a gross profit of RM64 thousand in 3Q2022, a 12.3% increase from a gross profit of RM57 thousand in 3Q2021, due mainly to sales efforts to garner bookings. Similarly for 9M2022, gross profit increased by 249.6% to RM430 thousand from gross profit of RM123 thousand for 9M2021.

Further due to reasons explained earlier, gross profit margin from Healthcare Services for 3Q2022 was 30.9% compared to 38.8% for 3Q2021. For Outsourced Services, the gross profit margin was 13.5% for 3Q2022. Gross profit margin for 9M2022 decreased to 20.2% from 22.1% for 9M2021 due mainly to higher sales promotions incurred by Healthcare services to garner more bookings during the period in review.

Other Operating Income

The Group reported other operating income for 3Q2022 of RM1.1 million compared to nil for 3Q2021, mainly due to (i) RM1.0 million gain on termination of a commercial space lease at the Mines Wellness City, Klang Valley, Malaysia that was proposed to be developed as the Mines2 confinement centre and (ii) RM50 thousand of government subsidies arising from

government restrictions on business activities to address the Covid-19 pandemic. Similarly, other operating income for 9M2022 of RM1.4 million comprised mainly of (i) RM1.0 million of the gain on termination of lease Mines2 confinement centre as mentioned above; (ii) RM0.2 million of rental rebates for the Mines2 confinement centre and (iii) RM0.1 million of Covid-19 related government subsidies. Other operating income of RM3 thousand recorded for 9M2021 was from government subsidies related to the Covid-19 pandemic.

Administrative Expenses

Administrative expenses in 3Q2022 decreased by 10.5% to RM1.3 million from RM1.4 million in 3Q2021 due mainly to: (i) net reduction in manpower cost of RM0.3 million due to attrition in manpower headcount and (ii) RM0.1 million reduction in marketing expenses. These decreases in administrative expenses were partially offset by an increase in overheads of RM0.2 million from Impact SG and Impact MY that was acquired during the fourth quarter of 2021. Depreciation of property, plant and equipment (“PPE”) for 3Q2022 decreased by 45.8% to RM13 thousand from RM24 thousand in 3Q2021 due to impairment of PPE related to the postpartum business during FY2021.

Administrative expenses in 9M2022 increased by 16.5% to RM4.1 million from RM3.5 million in 9M2021 due mainly to (i) increase in manpower and overheads of RM0.7 million from the acquisition of Impact SG and Impact MY during the fourth quarter of 2021; (ii) increase in depreciation of right-of-use assets of RM 0.1 million in relation to leases of office spaces in Singapore and Malaysia that were entered into in the second quarter of 2021 and (iii) corporate manpower costs of RM0.3 million that in 3Q2021 was previously recorded in HealthPro Pte Ltd that was placed under provisional liquidation on 29 July 2021 and thus reclassified as under discontinued operations. These increases in administrative expenses are partially offset by (i) RM0.2 million reduction in manpower cost from Healthcare services due to a headcount reduction and (ii) one-off RM0.2 million of legal and corporate costs for the issuance of convertible loans and the disposal of IEV Group Sdn Bhd that were incurred in 9M2021 but not in 9M2022. Depreciation of PPE for 9M2022 decreased by 37.7% to RM38 thousand from RM61 thousand in 9M2021 due to impairment of PPE related to the postpartum business during FY2021.

Exchange Gain/Loss

The Group recorded an exchange loss of RM118 thousand in 3Q2022 compared to an exchange gain of RM7 thousand in 3Q2021. For 9M2022, the Group recorded an exchange loss of RM223 thousand compared to an exchange loss of RM52 thousand for 9M2021. The exchange losses for 3Q2022 and 9M2022 were due to a strengthening Singapore Dollar against Malaysia Ringgit thereby increasing the costs of other payables of Malaysian subsidiaries that are denominated in Singapore Dollar.

Other Operating Expenses

Other operating expenses of RM130 thousand for 3Q2022 and RM133 thousand for 9M2022 are mainly due to (i) RM71 thousand impairment of trade receivables related human resource and payroll services; and (ii) RM60 thousand write-off of prepaid professional fees in relation to the termination of commercial space lease planned for the Mines2 Confinement Centre. In comparison, other operating expense of RM1.8 million for 9M2021 was due to an impairment of goodwill in view of delayed expansion plans and opening of the Group’s postpartum care centres in Malaysia as a result of Covid-19 pandemic induced suspension of various business activities. Additionally, plans for a large postpartum centre on Hendon Road, Singapore had been discontinued, being no longer commercially viable.

Finance Costs

Finance costs for 3Q2022 decreased by 56.6% to RM59 thousand from RM136 thousand for 3Q2021 due mainly to conversion of convertible loans with aggregate principal of S\$1.6 million into ordinary shares in the Company during FY2021. Finance cost for 9M2022 decreased by 23.2% to RM241 thousand from RM314 thousand for 9M2021 due mainly to a reduction in finance cost of RM135 thousand for convertible loans due to the aforementioned conversion of convertible loans; which was partially offset by a RM62 thousand increase in interest from finance lease obligations.

Loss Before Tax

For the reasons set out above, the Group recorded a loss before tax of RM0.3 million for 3Q2022 compared to a loss before tax of RM1.5 million for 3Q2021. For 9M2022, the Group recorded a loss before tax of RM2.9 million compared to a loss before tax of RM5.6 million for 9M2021.

Discontinued Operations

There was no loss from discontinued operations in 3Q2022 and 9M2022. Loss before tax from discontinued operations of RM2.6 million for 3Q2021 and RM6.6 million for 9M2021 was related to the voluntary liquidation of HealthPro Pte Ltd. The loss for 9M2021 mainly comprised of (i) RM 2.4 million loss for the liquidation of the subsidiary, (ii) depreciation of right-of-use assets of RM2.7 million for the lease of a commercial property, (iii) manpower costs of RM0.8 million and (iv) professional and consultancy services of RM0.5 million.

Review of Statement of Financial Position

Current Assets

The Group's trade receivables increased to RM1.0 million as at 30 September 2022 from RM0.5 million as at 31 December 2021 due mainly to the net addition of receivables from Outsourced Services. The Group's current portion of other receivables and prepayments decreased to RM0.5 million as at 30 September 2022 compared to RM1.0 million as at 31 December 2021 due mainly to RM0.4 million reduction of lease deposits used to offset outstanding lease payments in relation to the termination of the commercial lease space for the Mines2 Confinement Centre.

Non-Current Assets

Property plant and equipment ("PPE") marginally increased to RM215 thousand as at 30 September 2022 from RM157 thousand as at 31 December 2021 due mainly to renovation works of RM82 thousand for a corporate office in Malaysia and partially offset by depreciation charges of RM38 thousand for 9M2022. Right-of-use ("ROU") assets reduced by RM0.4 million to RM0.5 million as at 30 September 2022 from RM0.9 million as at 31 December 2021 due mainly to depreciation charges of RM0.3 million for office space leases in Singapore and Malaysia and reduction of RM0.2 million on the early termination of an office lease in Singapore. Intangible assets of RM0.2 million as at 30 September 2022 and 31 December 2021 relates to the acquisition of an e-Commerce platform to support the marketing and sales of the DNA profiling product "Qodify".

Capital and Reserves

Share capital of the Company and the Group increased by RM1.6 million to RM127.7 million as at 30 September 2022 from RM126.1 million as at 31 December 2021 due to the allotment and issuance of 44,247,788 new ordinary shares in the Company at an issue price of S\$0.0113 per ordinary share pursuant to a placement exercise. The Group's currency translation reserve as at 30 September 2022 was a marginal deficit of RM1 thousand compared to a reserve of RM22 thousand as at 31 December 2021 due to the strengthening of the Singapore dollar during the period in review.

Accumulated losses for the Group increased by RM2.9 million to RM138.9 million as at 30 September 2022 from RM136.0 million as at 31 December 2021 due to the loss recorded for 9M2022.

Non-Current Liabilities and Current Liabilities

Trade payables decreased to nil as at 30 September 2022 from RM31 thousand as at 31 December 2021 due to settlement of payables. Other payables for the Group as at 30 September 2022 increased by RM2.2 million to RM7.0 million from RM4.9 million as at 31 December 2021 due mainly to (i) RM1.6 million in accruals for corporate expenses; (ii) the addition of RM0.4 million in accruals incurred by the Healthcare business; (iii) the addition of RM0.1 million in accruals incurred by the Outsourcing business; and (iv) currency translation of RM0.1 million on Singapore Dollar denominated payables. Borrowings comprising convertible loans decreased by RM0.2 million to RM2.2 million as at 30 September 2022 from RM2.4 million as at 31 December 2021 due to RM0.5 million of principal settlement and interest pay-outs, which were partially offset by RM170 thousand of interest charges for 9M2022 and RM0.1 million of currency translation reserves.

Current and non-current lease liabilities as at 30 September 2022 decreased by RM2.0 million to RM0.5 million from RM2.5 million as at 31 December 2021 due mainly to (i) reduction of RM1.0 million from the termination of a commercial space lease for the Mines2 Confinement Centre; (ii) lease payments of RM0.9 million; and (iii) reduction of RM0.2 million from early termination of an office lease in Singapore. These decrease in lease liabilities were partially offset by lease interest of RM72 thousand for 9M2022.

Review of Statement of Cash Flows

For 3Q2022 the Group's net cash used in operating activities was RM1.2 million. This was mainly due to (i) an operating loss before working capital changes of RM1.1 million; (ii) reduction in trade and other payables of RM0.3 million and (iii) convertible loan interest payments of RM0.2 million; which was partially offset by a RM0.4 million reduction in trade and other receivables. Net cash used in investing activities of RM11 thousand for 3Q2022 was for the acquisition of plant and equipment related to health care services. Net cash generated from financing activities of RM1.0 million for 3Q2022 was from the net proceeds of RM1.6 million from a subscription to the Company's ordinary shares, which was partially offset by (i) RM0.3 million repayment of convertible loans and (ii) RM0.2 million repayment of lease liabilities.

For 9M2022, the Group used RM1.3 million in operating activities, mainly due to (i) RM3.2 million in operating loss before working capital changes and (ii) RM0.1 million increase in trade and other receivables, which were partially offset by RM2.1 million increase in trade and other payables. Net cash used in investing activities of RM0.1 million for 9M2022 was for the acquisition of plant and equipment related to office renovations and healthcare services. Net cash generated from financing activities of RM0.3 million for 9M2022 was mainly due to the net proceeds of RM1.6 million from issuance of ordinary shares, which was partially offset by (i) RM0.3 million repayment of convertible loans and (ii) RM0.9 million repayment of lease liabilities.

As a result of the above, the cash and cash equivalents was RM0.1 million as at 30 September 2022, compared to RM0.3 million as at 30 September 2021.

9. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

No forecast or prospect statement has been previously disclosed to shareholders.

10. A commentary at the date of the announcement of the significant trend competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

HEALTHCARE BUSINESS OVERVIEW

a) Malaysia

Since opening of international borders to non-Malaysians on 1 May 2022, all economic sectors in Malaysia have now resumed operations. However, labour shortages and the recent inflation has made economic recovery more challenging. Despite the challenges, the Group remains cautiously optimistic on the future prospects of the Healthcare Business, especially with the heightened public awareness on the need for good hygiene practices. Furthermore, the Group has been diligently maintaining the high quality of its postpartum care and complimentary treatment services, and at the same time, keeping a look out for opportunities within this sector.

b) Singapore

Singapore opened its doors to travellers since 1 April 2022, and is experiencing the same challenges as Malaysia, ie. labour shortages and inflation. However, the Group will continue to look out for viable opportunities in the healthcare and wellness space in Singapore.

OUTSOURCED SERVICES OVERVIEW

With the recent labour shortages, more businesses have given greater consideration to use outsource services such as recruitment and payroll processing, as they focus on revenue-generating activities. Our Outsourced service business is currently experiencing steady monthly growth and the Group will expand its offerings to cater to this segment, with a focus on the healthcare segment.

BUSINESS SEGMENT DEVELOPMENTS

i) Postpartum Care Centres

The PJ Confinement Centre at SS2 Petaling Jaya, Malaysia, continues to operate despite the current Covid-19 pandemic in Malaysia and at a very encouraging capacity. It has received bookings up to fourth quarter of 2022.

With regards to the Mines2 Confinement Centre in the Klang Valley region, Malaysia, the Group had experienced extended delays in the design and development phase of renovation works due to (i) Covid-19 related movement control orders and

(ii) protracted renovation application process with a local authority that required multiple re-submission of renovation plans and which has yet to be approved. In view of the above, the Group obtained consent from the landlord for an early termination of the commercial space lease at Mines Wellness City, Klang Valley, Malaysia. The Group continues to look for opportunities in this healthcare and wellness sector, including new postpartum care sites, in particular projects that require lower set up cost and investments.

ii) Chiropractic & Physiotherapy

The Group is currently operating its first chiropractic and physiotherapy centre at the PJ Confinement Centre since September 2021, under the brand name, 'Back To Life' ("BTL"). The month-on-month results have been promising and growing. The second BTL centre in Petaling Jaya, Malaysia has just commenced operations in November 2022. We are currently on the look out for more locations as we anticipate to set up an additional centre before year end.

Chiropractic and physiotherapy services have been heavily sought after in Malaysia for some time and demand is expected to continue to grow for the foreseeable years ahead. The rising trend of an active and sporting lifestyle amongst the young and old has significantly contributed to the high demand for such services. Thus, many new and standalone centres have opened in major population catchment areas to meet market demand.

iii) DNA Profiling

The Group is now focused on creating awareness and marketing of the Group's DNA profiling products, branded as "Qodify", to the Malaysia market. The Group has just commenced marketing and sales efforts in November 2022 on Qodify in Malaysia.

iv) Product distribution

With the recent relaxation of Covid19 prevention measures, the Group has redirected its applications efforts on the Lansonbio Dry Fluorescence Immunoassay Analyser ("Analyser") from Covid19 Antibody Test Kits to Brain Trauma Test Kits. The Group will re-initiate its approval application with the Malaysia government. At an appropriate opportunity and time, the Group intends to expand the market for this Analyser to include tests for diabetes, heart and hormonal conditions.

11. If a decision regarding dividend has been made:

(a) Whether an interim (final) ordinary dividend has been declared (recommended)

No.

(b) Previous corresponding period/rate %

None.

12. If no dividend has been declared (recommended), a statement to that effect

There is no interim dividend recommended and declared by the Directors in respect of the current financial period ended 30 September 2022 as the Group recorded a loss from its continuing operations in 9M2022.

13. Related party transactions and Interested Party Transaction ("IPT"). If the Group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect

Save for remuneration of directors and other members of key management during the financial period, there were no other related party transactions.

The Group does not have a general mandate from shareholders for interested person transactions ("IPTs") pursuant to Rule 920(1)(a)(ii) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "Catalist Rules"). There were no IPTs entered into during the financial period reported on which exceeds S\$100,000 in value.

14. Use of Proceeds from Share Subscription

Pursuant to Rule 1204(5)(f) of the Catalist Rules, the Board of Directors wishes to provide an update on the use of the proceeds arising from:

- (i) the entry into convertible loan agreements on 29 January 2021 for interest-bearing convertible loans (the "Convertible Loans") of approximately S\$2.185 million (after deducting expenses of approximately S\$65,000 incurred by the Company in connection with the Convertible Loans) have been utilised as follows:

Use of Proceeds	Amount allocated (as announced on 29 January 2021) (S\$'000)	Amount utilised as at 31 October 2022 (S\$'000)	Balance of net proceeds (S\$'000)
(i) Renovation and refurbishment of postpartum and chiropractic centres	1,300	1,130	170
(ii) Working capital	885	885 ⁽¹⁾	-
Total	2,185	2,015	170

Note 1. Working capital utilisation has been for (i) rental for commercial leases S\$565 thousand; (ii) payment of professional fees of S\$70 thousand; and (iii) manpower and overheads of S\$250 thousand.

- (ii) the allotment and issuance of 44,247,788 ordinary shares at an issue price of S\$0.0113 per share in the capital of the Company through a share subscription exercise (the “**Share Subscription**”) that was completed on 19 July 2022. The net proceeds of approximately S\$0.485 million (after deducting expenses of approximately S\$15,000 incurred by the Company in connection with the Share Subscription) have been utilised as follows:

Use of Proceeds	Amount allocated (as announced on 1 July 2022) (S\$'000)	Amount utilised as at 31 October 2022 (S\$'000)	Balance of net proceeds (S\$'000)
(i) Settlement of outstanding convertible loans	165	165	-
(ii) Renovation and refurbishment of postpartum and chiropractic centres	70	50	20
(ii) Working capital	250	125 ⁽¹⁾	125
Total	485	340	145

Note 1. Working capital utilisation has been for (i) rental for commercial leases S\$20 thousand; (ii) payment of professional fees of S\$25 thousand; and (iii) manpower and overheads of S\$80 thousand.

- (iii) the entry into non-redeemable convertible loan note agreements on 14 October 2022, 18 October 2022 and 31 October 2022 (“**CLNA Announcements**”) for interest-bearing non-redeemable convertible loan notes (the “**Convertible Loan Notes**”) of approximately S\$0.607 million (after deducting expenses of approximately S\$40,000 incurred by the Company in connection with the Convertible Loan Notes) have been utilised as follows:

Use of Proceeds	Amount allocated (as indicated in CLNA Announcements) (S\$'000)	Amount utilised as at 31 October 2022 (S\$'000)	Balance of net proceeds (S\$'000)
(i) Expansion of the Healthcare Business, including renovation and refurbishment of chiropractic centres in Singapore and Malaysia	110	-	110
(ii) Working capital	497	150 ⁽¹⁾	347
Total	607	150	457

Note 1. Working capital utilisation has been for (i) payment of professional fees of S\$40 thousand; and (ii) manpower and overheads of S\$110 thousand.

15. Confirmation by the Board of Directors pursuant to Rule 705(5) of the Catalist Rules

We, Low Koon Poh and Harry Ng, being Directors of the Company, do hereby confirm on behalf of the Board of Directors of the Company that, to the best of our knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the unaudited financial statements for the third quarter and nine months ended 30 September 2022 to be false or misleading in any material aspect.

16. Confirmation that the issuer has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1).

The Company confirms that all the required undertakings under the Rule 720(1) of the Catalist Rules have been obtained from its Directors and Executive Officers in the format set out in Appendix 7H of the Catalist Rules.

ON BEHALF OF THE BOARD OF DIRECTORS

LOW KOON POH EXECUTIVE CHAIRMAN & CEO	HARRY NG LEAD INDEPENDENT DIRECTOR
--	---------------------------------------

Date: 10 November 2022

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor").

This announcement has not been examined or approved by the Exchange and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.

The contact person for the Sponsor is Ms. Charmian Lim, at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542, telephone (65) 6232 3210.
